"ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death"  
NEJM Aug 8
http://www.nejm.org/doi/full/10.1056/NEJMoa1213299  

"CONCLUSIONS

ST2 levels measured at the initiation of therapy for GVHD and during the first month after transplantation improved risk stratification for treatment-resistant GVHD and death without relapse after transplantation. (Funded by the National Institutes of Health.)"